2019 Immune Thrombocytopenic Purpura R&D Pipeline Drugs, Companies, Trials and Developments
The global demand for Immune Thrombocytopenic Purpura treatment options is expected to report strong growth over the medium to long term future driven by consumption in major markets. Strong growth prospects of drugs for Immune Thrombocytopenic Purpura are driving leading companies to invest their resources on the pipeline.
Companies quickly advancing their drug candidates to advanced phases will evolve as top performers. However, challenges of completing clinical trials on schedules and inadequate financial support are holding some of the Immune Thrombocytopenic Purpura pipeline companies from advancing their products.
Immune Thrombocytopenic Purpura Report Description
The H1-2019 pipeline review report on Immune Thrombocytopenic Purpura is a comprehensive study on drug candidates across different phases worldwide. This report evaluates each of the pipeline products in terms of their current status, regulatory progress and expected phase completion date.
The Immune Thrombocytopenic Purpura pipeline guide presents information on all active drugs currently being developed for Immune Thrombocytopenic Purpura. The research work provides details of active therapeutic candidates in different phases including discovery, research, pre-clinical, phase I, Phase II, Phase III and pre-registration phases.
Details of current status, R&D progress and latest developments for every Immune Thrombocytopenic Purpura pipeline candidate are analyzed.
Further, current phase of development, mechanism of action, special designations such as orphan drug status, fast track designation, grants awarded, etc are presented for all Immune Thrombocytopenic Purpura drug candidates.
Drug development companies, collaborators, originating companies, license providers and universities participating in the Immune Thrombocytopenic Purpura product pipeline are provided. Company overview, snapshot and developments are provided for all participating companies.
The report assists in identifying potential upcoming companies and drugs in Immune Thrombocytopenic Purpura pipeline market along with progress of each drug. It also enables users to formulate effective strategies to stay ahead of competition.
The publisher has developed the report based on robust methodology for assessing pharmaceutical drugs, market sizes and sound forecast tools. All our research reports are provided through intense and repetitive primary and secondary research methods. The report is presented in a user-friendly format and presents clear and actionable insights.
Scope of Immune Thrombocytopenic Purpura pipeline report includes-
Companies quickly advancing their drug candidates to advanced phases will evolve as top performers. However, challenges of completing clinical trials on schedules and inadequate financial support are holding some of the Immune Thrombocytopenic Purpura pipeline companies from advancing their products.
Immune Thrombocytopenic Purpura Report Description
The H1-2019 pipeline review report on Immune Thrombocytopenic Purpura is a comprehensive study on drug candidates across different phases worldwide. This report evaluates each of the pipeline products in terms of their current status, regulatory progress and expected phase completion date.
The Immune Thrombocytopenic Purpura pipeline guide presents information on all active drugs currently being developed for Immune Thrombocytopenic Purpura. The research work provides details of active therapeutic candidates in different phases including discovery, research, pre-clinical, phase I, Phase II, Phase III and pre-registration phases.
Details of current status, R&D progress and latest developments for every Immune Thrombocytopenic Purpura pipeline candidate are analyzed.
Further, current phase of development, mechanism of action, special designations such as orphan drug status, fast track designation, grants awarded, etc are presented for all Immune Thrombocytopenic Purpura drug candidates.
Drug development companies, collaborators, originating companies, license providers and universities participating in the Immune Thrombocytopenic Purpura product pipeline are provided. Company overview, snapshot and developments are provided for all participating companies.
The report assists in identifying potential upcoming companies and drugs in Immune Thrombocytopenic Purpura pipeline market along with progress of each drug. It also enables users to formulate effective strategies to stay ahead of competition.
The publisher has developed the report based on robust methodology for assessing pharmaceutical drugs, market sizes and sound forecast tools. All our research reports are provided through intense and repetitive primary and secondary research methods. The report is presented in a user-friendly format and presents clear and actionable insights.
Scope of Immune Thrombocytopenic Purpura pipeline report includes-
- Snapshot of pipeline detailing number of active compounds, mergers and acquisitions, phase wise compounds, target areas, mechanism of action, trials etc
- Phase wise pipeline compounds
- Company wise list of pipeline compounds
- Mechanism of Action wise pipeline compounds
- For each pipeline product, the following details are provided-
- Snapshot (Drug, , Phase, Co Developer, Originator, Synonym, Orphan Drug Status, Type of Molecular Entity, Area)
- Current status of development
- Drug overview
- Mechanism of Action
- Pre-clinical and Clinical Trials
- The report is designed to help industry executives promote the success and continued growth of their organizations
- Get clear understanding of the entire Immune Thrombocytopenic Purpura pipeline, with details on active projects
- Stay ahead of the competition through comprehensive knowledge of Immune Thrombocytopenic Purpura pipeline progress
- Get in detail information of each product with updated information on each project along with key milestones
- Gain clear insights into the market through in-depth strategic analysis review
- Know the list of companies participating in global Immune Thrombocytopenic Purpura pipeline along with progress of each of the company’s products and information on associations/collaborations/licensing data
- Get trial information for each pipeline product under development
- Understand the pipeline structure in terms of mechanism of Action, phase and company
GLOBAL IMMUNE THROMBOCYTOPENIC PURPURA PIPELINE OVERVIEW
Key Findings, 2019
Disease Overview
Report Guide and Research Methodology
EXECUTIVE SUMMARY
Immune Thrombocytopenic Purpura Drugs under active development, H1@2019
Pipeline Drugs in Early Stage of Development (Pre-clinical, Discovery, Phase 1 and Phase 2)
Pipeline Drugs in Advanced Stage of Development (Phase 3, Pre-registration)
Companies involved in Immune Thrombocytopenic Purpura pipeline, H1@2019
Mechanism of Action wise Immune Thrombocytopenic Purpura Pipeline Candidates
AMGEN INC IMMUNE THROMBOCYTOPENIC PURPURA PIPELINE DETAILS
Business Profile
Drug Details
Drug Snapshot
Originator
Collaborator/Co-Developer
Route of Administration
Orphan Drug/Fast Track/Special Designation
Area
Type of Molecular Entity
Current Status
Drug Overview
Drug Mechanism of Action
Clinical/Pre-clinical Trial Details
Latest Drug Developments
ARGENX IMMUNE THROMBOCYTOPENIC PURPURA PIPELINE DETAILS
Business Profile
Drug Details
Drug Snapshot
Originator
Collaborator/Co-Developer
Route of Administration
Orphan Drug/Fast Track/Special Designation
Area
Type of Molecular Entity
Current Status
Drug Overview
Drug Mechanism of Action
Clinical/Pre-clinical Trial Details
Latest Drug Developments
BIOTEST AG IMMUNE THROMBOCYTOPENIC PURPURA PIPELINE DETAILS
Business Profile
Drug Details
Drug Snapshot
Originator
Collaborator/Co-Developer
Route of Administration
Orphan Drug/Fast Track/Special Designation
Area
Type of Molecular Entity
Current Status
Drug Overview
Drug Mechanism of Action
Clinical/Pre-clinical Trial Details
Latest Drug Developments
BIOVERATIV INC IMMUNE THROMBOCYTOPENIC PURPURA PIPELINE DETAILS
Business Profile
Drug Details
Drug Snapshot
Originator
Collaborator/Co-Developer
Route of Administration
Orphan Drug/Fast Track/Special Designation
Area
Type of Molecular Entity
Current Status
Drug Overview
Drug Mechanism of Action
Clinical/Pre-clinical Trial Details
Latest Drug Developments
CLOVER BIOPHARMACEUTICALS IMMUNE THROMBOCYTOPENIC PURPURA PIPELINE DETAILS
Business Profile
Drug Details
Drug Snapshot
Originator
Collaborator/Co-Developer
Route of Administration
Orphan Drug/Fast Track/Special Designation
Area
Type of Molecular Entity
Current Status
Drug Overview
Drug Mechanism of Action
Clinical/Pre-clinical Trial Details
Latest Drug Developments
CSL LTD IMMUNE THROMBOCYTOPENIC PURPURA PIPELINE DETAILS
Business Profile
Drug Details
Drug Snapshot
Originator
Collaborator/Co-Developer
Route of Administration
Orphan Drug/Fast Track/Special Designation
Area
Type of Molecular Entity
Current Status
Drug Overview
Drug Mechanism of Action
Clinical/Pre-clinical Trial Details
Latest Drug Developments
DOVA PHARMACEUTICALS INC IMMUNE THROMBOCYTOPENIC PURPURA PIPELINE DETAILS
Business Profile
Drug Details
Drug Snapshot
Originator
Collaborator/Co-Developer
Route of Administration
Orphan Drug/Fast Track/Special Designation
Area
Type of Molecular Entity
Current Status
Drug Overview
Drug Mechanism of Action
Clinical/Pre-clinical Trial Details
Latest Drug Developments
FUJIFILM HOLDINGS CORPORATION IMMUNE THROMBOCYTOPENIC PURPURA PIPELINE DETAILS
Business Profile
Drug Details
Drug Snapshot
Originator
Collaborator/Co-Developer
Route of Administration
Orphan Drug/Fast Track/Special Designation
Area
Type of Molecular Entity
Current Status
Drug Overview
Drug Mechanism of Action
Clinical/Pre-clinical Trial Details
Latest Drug Developments
GENOSCO INC IMMUNE THROMBOCYTOPENIC PURPURA PIPELINE DETAILS
Business Profile
Drug Details
Drug Snapshot
Originator
Collaborator/Co-Developer
Route of Administration
Orphan Drug/Fast Track/Special Designation
Area
Type of Molecular Entity
Current Status
Drug Overview
Drug Mechanism of Action
Clinical/Pre-clinical Trial Details
Latest Drug Developments
HANALL BIOPHARMA CO LTD IMMUNE THROMBOCYTOPENIC PURPURA PIPELINE DETAILS
Business Profile
Drug Details
Drug Snapshot
Originator
Collaborator/Co-Developer
Route of Administration
Orphan Drug/Fast Track/Special Designation
Area
Type of Molecular Entity
Current Status
Drug Overview
Drug Mechanism of Action
Clinical/Pre-clinical Trial Details
Latest Drug Developments
IMMUNOMEDICS INC IMMUNE THROMBOCYTOPENIC PURPURA PIPELINE DETAILS
Business Profile
Drug Details
Drug Snapshot
Originator
Collaborator/Co-Developer
Route of Administration
Orphan Drug/Fast Track/Special Designation
Area
Type of Molecular Entity
Current Status
Drug Overview
Drug Mechanism of Action
Clinical/Pre-clinical Trial Details
Latest Drug Developments
INTAS PHARMACEUTICALS IMMUNE THROMBOCYTOPENIC PURPURA PIPELINE DETAILS
Business Profile
Drug Details
Drug Snapshot
Originator
Collaborator/Co-Developer
Route of Administration
Orphan Drug/Fast Track/Special Designation
Area
Type of Molecular Entity
Current Status
Drug Overview
Drug Mechanism of Action
Clinical/Pre-clinical Trial Details
Latest Drug Developments
JIANGSU HENGRUI MEDICINE CO LTD IMMUNE THROMBOCYTOPENIC PURPURA PIPELINE DETAILS
Business Profile
Drug Details
Drug Snapshot
Originator
Collaborator/Co-Developer
Route of Administration
Orphan Drug/Fast Track/Special Designation
Area
Type of Molecular Entity
Current Status
Drug Overview
Drug Mechanism of Action
Clinical/Pre-clinical Trial Details
Latest Drug Developments
MOMENTA PHARMACEUTICALS INC IMMUNE THROMBOCYTOPENIC PURPURA PIPELINE DETAILS
Business Profile
Drug Details
Drug Snapshot
Originator
Collaborator/Co-Developer
Route of Administration
Orphan Drug/Fast Track/Special Designation
Area
Type of Molecular Entity
Current Status
Drug Overview
Drug Mechanism of Action
Clinical/Pre-clinical Trial Details
Latest Drug Developments
NOVARTIS AG IMMUNE THROMBOCYTOPENIC PURPURA PIPELINE DETAILS
Business Profile
Drug Details
Drug Snapshot
Originator
Collaborator/Co-Developer
Route of Administration
Orphan Drug/Fast Track/Special Designation
Area
Type of Molecular Entity
Current Status
Drug Overview
Drug Mechanism of Action
Clinical/Pre-clinical Trial Details
Latest Drug Developments
PFIZER INC IMMUNE THROMBOCYTOPENIC PURPURA PIPELINE DETAILS
Business Profile
Drug Details
Drug Snapshot
Originator
Collaborator/Co-Developer
Route of Administration
Orphan Drug/Fast Track/Special Designation
Area
Type of Molecular Entity
Current Status
Drug Overview
Drug Mechanism of Action
Clinical/Pre-clinical Trial Details
Latest Drug Developments
PRINCIPIA BIOPHARMA INC IMMUNE THROMBOCYTOPENIC PURPURA PIPELINE DETAILS
Business Profile
Drug Details
Drug Snapshot
Originator
Collaborator/Co-Developer
Route of Administration
Orphan Drug/Fast Track/Special Designation
Area
Type of Molecular Entity
Current Status
Drug Overview
Drug Mechanism of Action
Clinical/Pre-clinical Trial Details
Latest Drug Developments
PROTALEX INC IMMUNE THROMBOCYTOPENIC PURPURA PIPELINE DETAILS
Business Profile
Drug Details
Drug Snapshot
Originator
Collaborator/Co-Developer
Route of Administration
Orphan Drug/Fast Track/Special Designation
Area
Type of Molecular Entity
Current Status
Drug Overview
Drug Mechanism of Action
Clinical/Pre-clinical Trial Details
Latest Drug Developments
TAIHO PHARMACEUTICAL CO LTD IMMUNE THROMBOCYTOPENIC PURPURA PIPELINE DETAILS
Business Profile
Drug Details
Drug Snapshot
Originator
Collaborator/Co-Developer
Route of Administration
Orphan Drug/Fast Track/Special Designation
Area
Type of Molecular Entity
Current Status
Drug Overview
Drug Mechanism of Action
Clinical/Pre-clinical Trial Details
Latest Drug Developments
UCB SA IMMUNE THROMBOCYTOPENIC PURPURA PIPELINE DETAILS
Business Profile
Drug Details
Drug Snapshot
Originator
Collaborator/Co-Developer
Route of Administration
Orphan Drug/Fast Track/Special Designation
Area
Type of Molecular Entity
Current Status
Drug Overview
Drug Mechanism of Action
Clinical/Pre-clinical Trial Details
Latest Drug Developments
LATEST IMMUNE THROMBOCYTOPENIC PURPURA DRUG PIPELINE DEVELOPMENTS, 2019
APPENDIX
About Us
Sources and Methodology
Contact Information
Key Findings, 2019
Disease Overview
Report Guide and Research Methodology
EXECUTIVE SUMMARY
Immune Thrombocytopenic Purpura Drugs under active development, H1@2019
Pipeline Drugs in Early Stage of Development (Pre-clinical, Discovery, Phase 1 and Phase 2)
Pipeline Drugs in Advanced Stage of Development (Phase 3, Pre-registration)
Companies involved in Immune Thrombocytopenic Purpura pipeline, H1@2019
Mechanism of Action wise Immune Thrombocytopenic Purpura Pipeline Candidates
AMGEN INC IMMUNE THROMBOCYTOPENIC PURPURA PIPELINE DETAILS
Business Profile
Drug Details
Drug Snapshot
Originator
Collaborator/Co-Developer
Route of Administration
Orphan Drug/Fast Track/Special Designation
Area
Type of Molecular Entity
Current Status
Drug Overview
Drug Mechanism of Action
Clinical/Pre-clinical Trial Details
Latest Drug Developments
ARGENX IMMUNE THROMBOCYTOPENIC PURPURA PIPELINE DETAILS
Business Profile
Drug Details
Drug Snapshot
Originator
Collaborator/Co-Developer
Route of Administration
Orphan Drug/Fast Track/Special Designation
Area
Type of Molecular Entity
Current Status
Drug Overview
Drug Mechanism of Action
Clinical/Pre-clinical Trial Details
Latest Drug Developments
BIOTEST AG IMMUNE THROMBOCYTOPENIC PURPURA PIPELINE DETAILS
Business Profile
Drug Details
Drug Snapshot
Originator
Collaborator/Co-Developer
Route of Administration
Orphan Drug/Fast Track/Special Designation
Area
Type of Molecular Entity
Current Status
Drug Overview
Drug Mechanism of Action
Clinical/Pre-clinical Trial Details
Latest Drug Developments
BIOVERATIV INC IMMUNE THROMBOCYTOPENIC PURPURA PIPELINE DETAILS
Business Profile
Drug Details
Drug Snapshot
Originator
Collaborator/Co-Developer
Route of Administration
Orphan Drug/Fast Track/Special Designation
Area
Type of Molecular Entity
Current Status
Drug Overview
Drug Mechanism of Action
Clinical/Pre-clinical Trial Details
Latest Drug Developments
CLOVER BIOPHARMACEUTICALS IMMUNE THROMBOCYTOPENIC PURPURA PIPELINE DETAILS
Business Profile
Drug Details
Drug Snapshot
Originator
Collaborator/Co-Developer
Route of Administration
Orphan Drug/Fast Track/Special Designation
Area
Type of Molecular Entity
Current Status
Drug Overview
Drug Mechanism of Action
Clinical/Pre-clinical Trial Details
Latest Drug Developments
CSL LTD IMMUNE THROMBOCYTOPENIC PURPURA PIPELINE DETAILS
Business Profile
Drug Details
Drug Snapshot
Originator
Collaborator/Co-Developer
Route of Administration
Orphan Drug/Fast Track/Special Designation
Area
Type of Molecular Entity
Current Status
Drug Overview
Drug Mechanism of Action
Clinical/Pre-clinical Trial Details
Latest Drug Developments
DOVA PHARMACEUTICALS INC IMMUNE THROMBOCYTOPENIC PURPURA PIPELINE DETAILS
Business Profile
Drug Details
Drug Snapshot
Originator
Collaborator/Co-Developer
Route of Administration
Orphan Drug/Fast Track/Special Designation
Area
Type of Molecular Entity
Current Status
Drug Overview
Drug Mechanism of Action
Clinical/Pre-clinical Trial Details
Latest Drug Developments
FUJIFILM HOLDINGS CORPORATION IMMUNE THROMBOCYTOPENIC PURPURA PIPELINE DETAILS
Business Profile
Drug Details
Drug Snapshot
Originator
Collaborator/Co-Developer
Route of Administration
Orphan Drug/Fast Track/Special Designation
Area
Type of Molecular Entity
Current Status
Drug Overview
Drug Mechanism of Action
Clinical/Pre-clinical Trial Details
Latest Drug Developments
GENOSCO INC IMMUNE THROMBOCYTOPENIC PURPURA PIPELINE DETAILS
Business Profile
Drug Details
Drug Snapshot
Originator
Collaborator/Co-Developer
Route of Administration
Orphan Drug/Fast Track/Special Designation
Area
Type of Molecular Entity
Current Status
Drug Overview
Drug Mechanism of Action
Clinical/Pre-clinical Trial Details
Latest Drug Developments
HANALL BIOPHARMA CO LTD IMMUNE THROMBOCYTOPENIC PURPURA PIPELINE DETAILS
Business Profile
Drug Details
Drug Snapshot
Originator
Collaborator/Co-Developer
Route of Administration
Orphan Drug/Fast Track/Special Designation
Area
Type of Molecular Entity
Current Status
Drug Overview
Drug Mechanism of Action
Clinical/Pre-clinical Trial Details
Latest Drug Developments
IMMUNOMEDICS INC IMMUNE THROMBOCYTOPENIC PURPURA PIPELINE DETAILS
Business Profile
Drug Details
Drug Snapshot
Originator
Collaborator/Co-Developer
Route of Administration
Orphan Drug/Fast Track/Special Designation
Area
Type of Molecular Entity
Current Status
Drug Overview
Drug Mechanism of Action
Clinical/Pre-clinical Trial Details
Latest Drug Developments
INTAS PHARMACEUTICALS IMMUNE THROMBOCYTOPENIC PURPURA PIPELINE DETAILS
Business Profile
Drug Details
Drug Snapshot
Originator
Collaborator/Co-Developer
Route of Administration
Orphan Drug/Fast Track/Special Designation
Area
Type of Molecular Entity
Current Status
Drug Overview
Drug Mechanism of Action
Clinical/Pre-clinical Trial Details
Latest Drug Developments
JIANGSU HENGRUI MEDICINE CO LTD IMMUNE THROMBOCYTOPENIC PURPURA PIPELINE DETAILS
Business Profile
Drug Details
Drug Snapshot
Originator
Collaborator/Co-Developer
Route of Administration
Orphan Drug/Fast Track/Special Designation
Area
Type of Molecular Entity
Current Status
Drug Overview
Drug Mechanism of Action
Clinical/Pre-clinical Trial Details
Latest Drug Developments
MOMENTA PHARMACEUTICALS INC IMMUNE THROMBOCYTOPENIC PURPURA PIPELINE DETAILS
Business Profile
Drug Details
Drug Snapshot
Originator
Collaborator/Co-Developer
Route of Administration
Orphan Drug/Fast Track/Special Designation
Area
Type of Molecular Entity
Current Status
Drug Overview
Drug Mechanism of Action
Clinical/Pre-clinical Trial Details
Latest Drug Developments
NOVARTIS AG IMMUNE THROMBOCYTOPENIC PURPURA PIPELINE DETAILS
Business Profile
Drug Details
Drug Snapshot
Originator
Collaborator/Co-Developer
Route of Administration
Orphan Drug/Fast Track/Special Designation
Area
Type of Molecular Entity
Current Status
Drug Overview
Drug Mechanism of Action
Clinical/Pre-clinical Trial Details
Latest Drug Developments
PFIZER INC IMMUNE THROMBOCYTOPENIC PURPURA PIPELINE DETAILS
Business Profile
Drug Details
Drug Snapshot
Originator
Collaborator/Co-Developer
Route of Administration
Orphan Drug/Fast Track/Special Designation
Area
Type of Molecular Entity
Current Status
Drug Overview
Drug Mechanism of Action
Clinical/Pre-clinical Trial Details
Latest Drug Developments
PRINCIPIA BIOPHARMA INC IMMUNE THROMBOCYTOPENIC PURPURA PIPELINE DETAILS
Business Profile
Drug Details
Drug Snapshot
Originator
Collaborator/Co-Developer
Route of Administration
Orphan Drug/Fast Track/Special Designation
Area
Type of Molecular Entity
Current Status
Drug Overview
Drug Mechanism of Action
Clinical/Pre-clinical Trial Details
Latest Drug Developments
PROTALEX INC IMMUNE THROMBOCYTOPENIC PURPURA PIPELINE DETAILS
Business Profile
Drug Details
Drug Snapshot
Originator
Collaborator/Co-Developer
Route of Administration
Orphan Drug/Fast Track/Special Designation
Area
Type of Molecular Entity
Current Status
Drug Overview
Drug Mechanism of Action
Clinical/Pre-clinical Trial Details
Latest Drug Developments
TAIHO PHARMACEUTICAL CO LTD IMMUNE THROMBOCYTOPENIC PURPURA PIPELINE DETAILS
Business Profile
Drug Details
Drug Snapshot
Originator
Collaborator/Co-Developer
Route of Administration
Orphan Drug/Fast Track/Special Designation
Area
Type of Molecular Entity
Current Status
Drug Overview
Drug Mechanism of Action
Clinical/Pre-clinical Trial Details
Latest Drug Developments
UCB SA IMMUNE THROMBOCYTOPENIC PURPURA PIPELINE DETAILS
Business Profile
Drug Details
Drug Snapshot
Originator
Collaborator/Co-Developer
Route of Administration
Orphan Drug/Fast Track/Special Designation
Area
Type of Molecular Entity
Current Status
Drug Overview
Drug Mechanism of Action
Clinical/Pre-clinical Trial Details
Latest Drug Developments
LATEST IMMUNE THROMBOCYTOPENIC PURPURA DRUG PIPELINE DEVELOPMENTS, 2019
APPENDIX
About Us
Sources and Methodology
Contact Information
